federal_register: 2018-26034

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2018-26034 Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use; Draft Guidance for Industry and Food and Drug Administration Staff; Availability Notice The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance for industry and FDA staff entitled "Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use." This draft guidance document describes studies and criteria that FDA recommends be used when submitting premarket notifications (510(k)s) for blood glucose monitoring systems (BGMSs) that are for prescription point-of-care use. This draft guidance is not final nor is it in effect at this time. 2018-11-30 2018 11 https://www.federalregister.gov/documents/2018/11/30/2018-26034/blood-glucose-monitoring-test-systems-for-prescription-point-of-care-use-draft-guidance-for-industry https://www.govinfo.gov/content/pkg/FR-2018-11-30/pdf/2018-26034.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance for industry and FDA staff entitled "Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use." This draft guidance document describes...

Links from other tables